Evidence map›Paper›PMID 41513675›Full record

ArticleScientific data2026

Clinical and dosimetric dataset of time-to-event normal tissue complication probability for osteoradionecrosis.

Natalie A West, Serageldin Kamel, Andrew Wentzel, Zaphanlene Kaffey, Moamen Abdelaal, G Elisabeta Marai, Guadalupe Canahuate, Xinhua Zhang, Melissa M Chen, Kareem A Wahid and 14 more

Abstract readDataset
In one paragraph

Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Advancing Normal Tissue Complication Probability Modeling with Supervised Contrastive Learning for Predicting Osteoradionecrosis.Proceedings of the ... Symposium on Applied Computing. Symposium on Applied Computing · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Natalie A WestThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. nawest@mdanderson.org.ORCID http://orcid.org/0009-0007-0211-8845
Serageldin KamelThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew WentzelUniversity of Illinois Chicago, Chicago, IL, USA.
Zaphanlene KaffeyThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Moamen AbdelaalUniversity of Illinois Chicago, Chicago, IL, USA.
G Elisabeta MaraiUniversity of Illinois Chicago, Chicago, IL, USA.
Guadalupe CanahuateUniversity of Iowa, Iowa City, IA, USA.
Xinhua ZhangBaylor College of Medicine, Houston, TX, USA.
Melissa M ChenThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kareem A WahidThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0503-0175
Jillian RigertThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kristy K BrockThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark ChambersThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adegbenga O OtunThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruth Aponte-WessonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renjie HeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mohamed A NaserThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1020-4966
Katherine A HutchesonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abdallah S R MohamedThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2064-7613
Lisanne V van DijkUniversity Medical Center Groningen, Groningen, Netherlands.
Amy C MorenoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephen Y LaiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clifton D FullerThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. cdfuller@mdanderson.org.ORCID http://orcid.org/0000-0002-5264-3994
Laia Humbert-VidanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. lhumbertvidan@gmail.com.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Project 3: OPC-RADP01CA285249 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Clifton David Fuller, Katherine Arnold Hutcheson · 2024 to 2026
$9.4M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
Integration and interoperability of complex data and tissues from the human brainUG3TR004501 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LOEB, JEFFREY A · 2023 to 2025
$3.1M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
Longitudinal Spatial-Nonspatial Decision Support for Competing Outcomes in Head and Neck Cancer TherapyR01CA258827 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2021 to 2025
$2.9M
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)U01DE032168 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Clifton David Fuller, STEPHEN Y LAI · 2023 to 2026
$2.8M
Image Guided Cancer Therapy Training ProgramT32CA261856 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kristy Brock, Clifton David Fuller · 2022 to 2026
$1.2M
CTSA Predoctoral T32 at the University of Texas Health Science Center at HoustonT32TR004905 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Joya Chandra, Jeffrey A. Frost · 2024 to 2026
$811k
Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER)R03DE033550 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, NASER, MOHAMED · 2024 to 2025
$499k
Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP210042KWF Kankerbestrijding (Dutch Cancer Society) KWF-13529National Science Foundation (NSF) CNS-2320261NCATS NIH HHS T32 TR004905NCATS NIH HHS UG3 TR004501NCI NIH HHS K12 CA088084NCI NIH HHS P01 CA285249NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA258827NCI NIH HHS T32 CA261856NIDCR NIH HHS K01 DE030524NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R01 DE028290NIDCR NIH HHS R03 DE033550NIDCR NIH HHS R21 DE031082NIDCR NIH HHS U01 DE032168U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA016672U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA016672-47U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA016672-48U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA258827U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) 1R01DE028290-01A1U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) K01DE030524U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) K12CA088084U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R01DE025248U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R01DE028290U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R01DE028290-02S1U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R03DE033550U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R21DE031082U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) U01DE032168ZonMw (Netherlands Organisation for Health Research and Development) NWO-09150162010173
6 · The paper itself

Abstract

Osteoradionecrosis of the jaw (ORNJ) is a radiation-induced late toxicity that can dramatically decrease patients' quality of life. Recent increases in survival rates of head and neck cancers associated with human papillomavirus (HPV) infection have resulted in a higher frequency of radiation-induced toxicities, particularly ORNJ. Recent work with Normal Tissue Complication Probability (NTCP) models and a Weibull Accelerated Failure Time (WAFT) model have further developed our understanding of ORNJ clinical/dosimetric risk factors and longitudinal features, respectively. In this data descriptor, 1129 head and neck cancer (HNC) patients received curative intent radiotherapy (RT) at MD Anderson Cancer Center and were followed up with clinical and radiological assessments at 3-6, 12, 18, 24 months, and then annually following the conclusion of RT for development of ORNJ. This data, in addition to the patients' demographic, supplementary clinical, and dosimetric information was recorded in a comma-separated value file embedded within this data descriptor. This large, longitudinal dataset is a significant resource for further systematic analysis of post-RT normal tissue outcomes in HNC.

Indexed as

Head and Neck NeoplasmsOsteoradionecrosisAgedFemaleHumansMaleMiddle AgedProbability

Identifiers

PMID41513675
PMCPMC12796154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.